Emerging Markets Earnings: Amgen’s International Push Pays Off
This article was originally published in PharmAsia News
Amgen hails international growth, but provides few cues on when biosimilar competition for key products may hit those markets.
You may also be interested in...
Amgen is building a cardiovascular commercial team as it prepares to move into the new therapeutic category. It expects to launch ivabradine for heart failure first followed by evolocumab for high cholesterol.
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.